Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligence

Area of Science:

• Gastroenterology and Immunology
• Computational Biology and Bioinformatics

Background:

• Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, arises from a complex interplay of genetic, environmental, and lifestyle factors.
• The heterogeneity of IBD presents significant challenges in improving disease management, treatment strategies, and understanding genetic and exposome influences.

Purpose of the Study:

• To review current advancements in IBD research utilizing omics technologies (genomics, transcriptomics, proteomics, metagenomics) and multi-omics approaches.
• To explore the role of artificial intelligence (AI) in integrating complex, heterogeneous datasets for a deeper understanding of IBD pathogenesis and progression.
• To identify knowledge gaps and inform future research directions in IBD, aiming towards the realization of precision medicine.

Main Methods:

• Comprehensive literature review of individual omics (genomics, transcriptomics, proteomics, metagenomics) and multi-omics studies in IBD.
• Analysis of the application of systems biology tools and artificial intelligence (AI) in processing large-scale biological and clinical datasets.
• Synthesis of current understanding and identification of research gaps based on the reviewed literature.

Main Results:

• Multi-omics research and AI approaches are crucial for deciphering the complex interactions influencing IBD.
• These innovative methods, powered by big data, enhance the understanding of disease natural history, predictors, severity, complications, and treatment outcomes.
• AI facilitates the integration of diverse data types, offering decision support for clinicians and advancing precision medicine in IBD.

Conclusions:

• The integration of omics data with AI holds significant promise for unraveling the complexities of IBD.
• This synergistic approach is essential for developing more effective diagnostic and therapeutic strategies, ultimately improving patient care and outcomes in IBD.
• Further research is needed to fully leverage these technologies for personalized treatment approaches in IBD.